Search clinical trials for: EGFR mutation-positive

Total 1597 results

Chinese PLA General Hospital

Recruiting

TGFβR-KO CAR-EGFR T Cells in Previously Treated Advanced EGFR-positive Solid Tumors

Solid Tumor, Adult | EGFR Overexpression

China
Qingdao Central Hospital

Recruiting

Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

China
Qingdao Central Hospital

Recruiting

Tyrosine Kinase Inhibitors in Metastastic Adenoid Cystic Carcinoma

Carcinoma, Adenoid Cystic

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Camrelizumab Combined With Pemetrexed and Carboplatin for the Study of EGFR-mutated Lung Squamous NSCLC Treatment

Lung Cancer Stage II
Tianjin Medical University Cancer Institute and...
Allist Pharmaceuticals, Inc.

Not yet recruiting

Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT)

Lung Adenocarcinoma
Anthony Magliocco

Recruiting

Idylla EGFR Lung Trial

Lung Cancer | Oncology | Technology

United States
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation

Non-small Cell Lung Cancer

China
National Cancer Centre, Singapore
Singapore Translational Cancer Consortium; Genome Institute of Singapore; Cancer...

Recruiting

Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers

Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Advanced Solid Tumours

Singapore
Second Affiliated Hospital of Nanchang University
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis (ATTRACT)

NSCLC | EGFR Activating Mutation | Leptomeningeal Metastasis

China
Crimson Biopharm Inc.

Not yet recruiting

CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM)

Glioblastoma
Betta Pharmaceuticals Co., Ltd.

Recruiting

Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

Head and Neck Cancer | Colorectal Cancer | Non-Small Cell Lung Cancer | Solid Tumor

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Aumolertinib With or Without Chemotherapy as 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Sensitizing EGFR Mutations

Non-small Cell Lung Cancer

China
Baohui Han
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Aumolertinib Adjuvant Therapy of Resectable Stage I EGFRm+ NSCLC With High-grade Patterns (APPOINT)

Lung Cancer

China
Samsung Medical Center
GENECAST Co., Ltd.

Recruiting

Practical Usability of EGFR Mutation Detection in ctDNA From Resectable NSCLC

Lung Neoplasms

Korea, Republic of
Institut Bergonié
AstraZeneca

Recruiting

Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients (CIRCULAR)

Non Small Cell Lung Cancer | Advanced Solid Tumor

France
National University Hospital, Singapore
Boehringer Ingelheim

Recruiting

Observational Study of Afatinib 30 mg Daily

Non-Small Cell Lung Cancer | Epidermal Growth Factor Receptor Mutation

Singapore
Chongqing University Cancer Hospital

Recruiting

Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC

Non-Small Cell Lung Cancer (NSCLC)

China
Duke University

Not yet recruiting

Bispecific T Cell Engager BRiTE for Patients With Grade IV Malignant Glioma (BRiTE)

Glioblastoma | Malignant Glioma

United States
Massachusetts General Hospital
American Lung Association

Recruiting

Patient-centered, Optimal Integration of Survivorship and Palliative Care

Carcinoma, Non-Small-Cell Lung | Nonsmall Cell Lung Cancer | Palliative Care | Survivorship | Targeted Therapy | Stage IV Non-small Cell Lung Cancer | EGFR Positive Non-small Cell Lung Cancer | ALK-positive Non-small Cell Lung Cancer

United States
Shanghai Chest Hospital
Allist Pharmaceuticals, Inc.

Recruiting

Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC (FOCUS-A)

Non-Small-Cell Lung Cancer

China
Shanghai Chest Hospital
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment (ACTIVE)

Lung Cancer | EGFR Gene Mutation
Peking University

Not yet recruiting

Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification

Esophageal Squamous Cell Carcinoma

China
Hospices Civils de Lyon

Not yet recruiting

Evaluation of a Cosmetic Product to Preserve Skin Conditions When Using Anti-EGFR Cancer Therapies (OPERA)

Head and Neck Neoplasms | Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms

France
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications

Renal Allograft Recipients

France, Germany, Spain, United Kingdom, Italy, Netherlands, Belgium, United States
Beijing Dongfang Biotech Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Not yet recruiting

JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety

NSCLC
Shanghai Chest Hospital

Not yet recruiting

Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases (ATTACK)

NSCLC
Merus N.V.

Recruiting

A Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

Gastric Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Non-Small Cell Lung Cancer Metastatic

United States, Spain, France, Italy, Netherlands, Belgium, Korea, Republic of, Germany, Singapore
Shanghai Miracogen Inc.

Recruiting

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

China
Lady Davis Institute

Recruiting

Doxycycline vs Isotretinoin for Acneiform Eruptions of TKI

Acneiform Eruptions | Cancer, Treatment-Related

Canada
Takeda

Recruiting

A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer

Colorectal Cancer | Non-small Cell Lung Cancer (NSCLC) | Squamous Cell Cancer of Head and Neck (SCCHN)

Korea, Republic of, United States, Australia
Second Affiliated Hospital of Guangzhou Medical...
Guangdong Zhaotai InVivo Biomedicine Co. Ltd.

Recruiting

Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors

Breast Cancer | Lung Cancer | Brain Tumor | Colo-rectal Cancer | Liver Cancer | Solid Tumor, Adult | CTLA4 | PD1

China
Nanjing Sanhome Pharmaceutical, Co., Ltd.

Recruiting

A Study to Investigate Safety and Tolerability of SH3809 Tablet in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Guangdong Association of Clinical Trials
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

MRD Guiding Treatment After Almonertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model. (APPROACH)

Lung Cancer

China
Shanghai Miracogen Inc.

Recruiting

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG003 in the Treatment of EGFR-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer

Advanced or Metastatic Biliary Tract Cancer

China
Hui Bu

Recruiting

Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer

Lung Cancer | Leptomeningeal Metastasis

China
Sixth Affiliated Hospital, Sun Yat-sen University

Recruiting

Steroids Therapy in IgA Nephropathy With Crescents

IgA Nephropathy

China
The First Affiliated Hospital of Guangzhou Medical...

Recruiting

A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China

NSCLC, Stage III | NSCLC, Stage I | NSCLC, Stage II

China
Medolution Ltd.

Recruiting

Keynatinib in Treated Patients With NSCLC and Brain Metastases

Brain Metastases | Non-Small Cell Lung Cancer With EGFR Mutation

China
Novartis Pharmaceuticals

Recruiting

Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. (APPEAR-C3G)

C3G

Spain, France, Switzerland, Germany, Greece, Turkey, United States, Canada, India, Czechia, Japan, Brazil, Italy, Argentina, Israel, United Kingdom, Netherlands, Belgium, China
Yonsei University

Recruiting

A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Neoadjuvant Osimertinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harbouring EGFR Mutations

Non Small Cell Lung Cancer

Korea, Republic of
Fondazione Ricerca Traslazionale

Recruiting

Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations (CAPLAND)

NSCLC

Italy
Naestved Hospital

Recruiting

Oncodrivers in Malignant Pleural Effusions Associated With Non-small Cell Lung Cancer: A Prospective Study.

Non-small Cell Lung Cancer | Malignant Pleural Effusion

Denmark
SOLTI Breast Cancer Research Group
Novartis

Recruiting

Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors (ACROPOLI)

Melanoma | Sarcoma | Small Cell Lung Cancer | Hepatocellular Carcinoma | Pancreatic Adenocarcinoma | Uterine Carcinosarcoma | Mesothelioma | Cholangiocarcinoma | Lung Adenocarcinoma | Triple Negative Breast Cancer | Epithelial Ovarian Cancer | HER2-positive Breast Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal... and other conditions

Spain
Tianjin Medical University Cancer Institute and...

Recruiting

Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC (SAINT)

Non Small Cell Lung Cancer

China
Sun Yat-sen University

Recruiting

Almonertinib Combined With Pyrotinib in the Treatment of Advanced NSCLC Patients With HER-2 Amplification/Mutation After EGFR-TKI Resistance (APPEAR)

Safety

China
Henan Cancer Hospital

Recruiting

A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)

NSCLC | Brain Metastases | Leptomeningeal Metastasis

China
Ohio State University Comprehensive Cancer Center

Recruiting

Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8

United States
National Guard Health Affairs

Recruiting

A Prospective Study Utilizing Circulating Cell Free DNA (cfDNA) Use in the Detection of RAS Mutations in Patients With Advanced Colorectal Cancer.

Colon Cancer

Saudi Arabia

Search clinical trials for: EGFR mutation-positive

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Colombia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations